TEAD4 and breast cancer: Consistent with these findings, high levels of YAP correlate with a longer relapse-free survival rate and good tamoxifen treatment outcome in ER+ breast cancer patients while high levels of MST1/2 or TEAD4 correlate with poor prognosis.